Matches in SemOpenAlex for { <https://semopenalex.org/work/W1528174880> ?p ?o ?g. }
- W1528174880 endingPage "145" @default.
- W1528174880 startingPage "121" @default.
- W1528174880 abstract "Since the isolation of the gene and mutation that cause Huntington’s disease (HD) more than a decade ago, there has been optimism that this knowledge would lead to the rapid discovery of therapeutic agents for this fatal and incurable disease [1]. In fact, considerable effort has been invested in HD drug discovery, predominantly in academic environments but also in the biopharmaceutical industry to some certain extent. Historically, however, interest in HD research and development in large pharmaceutical firms has been limited by the relatively small size of the HD patient population (~30,000 affected persons in United States), which has led to the perception that the market size for HD might be too small to justify the investment of substantial resources necessary to bring a new drug to clinical trials. However, there is a growing appreciation for the actual market size of “first in class” drugs for otherwise unaddressable diseases, as well as for the idea that HD may prove to be a paradigmatic disease for other, much more prevalent neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease [2].One hurdle in drug discovery for most neurodegenerative disorders is their incompletely understood, multigenic, and multifactorial etiology. Thus, animal models of these diseases may often recapitulate only some aspects of such diseases and rarely reproduce the full pathophysiology of the human diseases [3], [4]. In contrast, HD is caused by a well-defined mutation in a single autosomal gene that has a dominant and fully penetrant phenotype. This simplicity in the genetics of HD has allowed the creation of a variety of cells cultures and transgenic animal models for HD in which there can be greater confidence that these models do capture important aspects of human disease initiation and progression [5].This chapter will focus on the development and implementation of high-throughput and high-content in vitro assays for the discovery of HD therapeutics. High-throughput screening (HTS) of small molecules allows the rapid interrogation of the effects of thousands to hundreds of thousands of small molecules in a variety of in vitro and cell-based assays, whereas high-content screening (HCS) approaches may sacrifice some of these high-throughput capabilities in return for great biological and phenotypic complexity in the assay endpoints used. Why do we need such high-throughput and high-content methods? Simply because we do not currently have sufficient knowledge of the molecular targets and pathways that may be therapeutic for HD nor do we know how to design a priori custom small molecule compounds that will be guaranteed to have the desired effect on such biological targets. Hence rapid testing of many tens of thousands or more drug molecule candidates in HD models offers the potential for systematized serendipity, that we will encounter effective compounds in such discovery campaigns that will prove to be clinically relevant, using controllable and predictable in vitro screening processes.Active compounds emerging from HTS and HCS screens—termed “hits”—are the templates on which eventually drug “leads” are developed through further combinatorial and medicinal chemistry efforts Figure 5.1. Such efforts in the field have identified a number of hits that are being pursued as drug leads (see Chapters 8 and 12, this volume). In the following sections we will describe different strategies and approaches in the design and implementation of HTS and HCS screens for HD, and will also discuss the development of prioritization schemes for potential drug leads identified, future screening approaches, and the use of these compounds for gaining new insights into mechanisms underlying HD." @default.
- W1528174880 created "2016-06-24" @default.
- W1528174880 creator A5001783135 @default.
- W1528174880 creator A5011366823 @default.
- W1528174880 creator A5030207693 @default.
- W1528174880 date "2010-07-02" @default.
- W1528174880 modified "2023-10-06" @default.
- W1528174880 title "High-Throughput and High-Content Screening for Huntington's Disease Therapeutics" @default.
- W1528174880 cites W1582327855 @default.
- W1528174880 cites W1608885177 @default.
- W1528174880 cites W1643390591 @default.
- W1528174880 cites W1892455234 @default.
- W1528174880 cites W1966815691 @default.
- W1528174880 cites W1967804794 @default.
- W1528174880 cites W1969083180 @default.
- W1528174880 cites W1974682598 @default.
- W1528174880 cites W1981326800 @default.
- W1528174880 cites W1982170400 @default.
- W1528174880 cites W1982623268 @default.
- W1528174880 cites W1983627476 @default.
- W1528174880 cites W1991001144 @default.
- W1528174880 cites W1991354828 @default.
- W1528174880 cites W1992921611 @default.
- W1528174880 cites W1995591507 @default.
- W1528174880 cites W1996242123 @default.
- W1528174880 cites W2001086078 @default.
- W1528174880 cites W2005927762 @default.
- W1528174880 cites W2007719003 @default.
- W1528174880 cites W2008731781 @default.
- W1528174880 cites W2011796077 @default.
- W1528174880 cites W2013144569 @default.
- W1528174880 cites W2014446045 @default.
- W1528174880 cites W2015214742 @default.
- W1528174880 cites W2018928754 @default.
- W1528174880 cites W2025757297 @default.
- W1528174880 cites W2052983466 @default.
- W1528174880 cites W2054648295 @default.
- W1528174880 cites W2061497413 @default.
- W1528174880 cites W2061627162 @default.
- W1528174880 cites W2066024683 @default.
- W1528174880 cites W2068261374 @default.
- W1528174880 cites W2074370114 @default.
- W1528174880 cites W2076290065 @default.
- W1528174880 cites W2076987187 @default.
- W1528174880 cites W2078784691 @default.
- W1528174880 cites W2079250951 @default.
- W1528174880 cites W2082890051 @default.
- W1528174880 cites W2085165928 @default.
- W1528174880 cites W2085449884 @default.
- W1528174880 cites W2086266092 @default.
- W1528174880 cites W2089657508 @default.
- W1528174880 cites W2090863707 @default.
- W1528174880 cites W2095099413 @default.
- W1528174880 cites W2105649494 @default.
- W1528174880 cites W2115283962 @default.
- W1528174880 cites W2121264285 @default.
- W1528174880 cites W2121760835 @default.
- W1528174880 cites W2123004324 @default.
- W1528174880 cites W2125527752 @default.
- W1528174880 cites W2127294578 @default.
- W1528174880 cites W2130839195 @default.
- W1528174880 cites W2135732933 @default.
- W1528174880 cites W2135732941 @default.
- W1528174880 cites W2137580576 @default.
- W1528174880 cites W2141474275 @default.
- W1528174880 cites W2145408804 @default.
- W1528174880 cites W2147766249 @default.
- W1528174880 cites W2153019714 @default.
- W1528174880 cites W2156179144 @default.
- W1528174880 cites W2162226305 @default.
- W1528174880 cites W2163018106 @default.
- W1528174880 cites W2163142681 @default.
- W1528174880 cites W2164973029 @default.
- W1528174880 cites W2167960276 @default.
- W1528174880 cites W2172197220 @default.
- W1528174880 cites W2184280554 @default.
- W1528174880 cites W2317034342 @default.
- W1528174880 cites W2600639051 @default.
- W1528174880 doi "https://doi.org/10.1201/ebk0849390005-c5" @default.
- W1528174880 hasPublicationYear "2010" @default.
- W1528174880 type Work @default.
- W1528174880 sameAs 1528174880 @default.
- W1528174880 citedByCount "6" @default.
- W1528174880 countsByYear W15281748802012 @default.
- W1528174880 countsByYear W15281748802013 @default.
- W1528174880 countsByYear W15281748802018 @default.
- W1528174880 countsByYear W15281748802020 @default.
- W1528174880 countsByYear W15281748802021 @default.
- W1528174880 crossrefType "book-chapter" @default.
- W1528174880 hasAuthorship W1528174880A5001783135 @default.
- W1528174880 hasAuthorship W1528174880A5011366823 @default.
- W1528174880 hasAuthorship W1528174880A5030207693 @default.
- W1528174880 hasConcept C118552586 @default.
- W1528174880 hasConcept C142724271 @default.
- W1528174880 hasConcept C2779134260 @default.
- W1528174880 hasConcept C2779652045 @default.
- W1528174880 hasConcept C2780035454 @default.
- W1528174880 hasConcept C2780647506 @default.